173 related articles for article (PubMed ID: 22227588)
1. Treatment-for-prevention: clinical considerations.
Lockman S; Sax P
Curr Opin HIV AIDS; 2012 Mar; 7(2):131-9. PubMed ID: 22227588
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda.
Dieffenbach CW
Curr Opin HIV AIDS; 2012 Mar; 7(2):106-10. PubMed ID: 22227584
[TBL] [Abstract][Full Text] [Related]
4. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.
Forsyth AD; Valdiserri RO
Curr Opin HIV AIDS; 2012 Mar; 7(2):111-6. PubMed ID: 22227586
[TBL] [Abstract][Full Text] [Related]
5. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
6. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
7. Using HIV viral load to guide treatment-for-prevention interventions.
Novitsky V; Essex M
Curr Opin HIV AIDS; 2012 Mar; 7(2):117-24. PubMed ID: 22258501
[TBL] [Abstract][Full Text] [Related]
8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in treatment-naïve patients with HIV infection.
Camacho R; Teófilo E
Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S3-11. PubMed ID: 22156777
[TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
12. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
13. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
15. Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy.
Lihana RW; Lwembe RM; Bi X; Ochieng W; Panikulam A; Palakudy T; Musoke R; Owens M; Ishizaki A; Okoth FA; Songok EM; Ichimura H
J Clin Virol; 2011 Oct; 52(2):123-8. PubMed ID: 21798798
[TBL] [Abstract][Full Text] [Related]
16. Structured treatment interruptions--new findings.
Benson CA
Top HIV Med; 2006; 14(3):107-11. PubMed ID: 16946455
[TBL] [Abstract][Full Text] [Related]
17. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
18. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
[TBL] [Abstract][Full Text] [Related]
19. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
Grant PM; Zolopa AR
Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
[TBL] [Abstract][Full Text] [Related]
20. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B;
Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
